Drug Delivery

 

Access to the cytosol is a fundamental requirement for the efficacy of cell-based therapeutics. Nanocarrier technologies promote cellular uptake, but the vast majority rely on inefficient endosomal uptake/release pathways.

Our research harnesses the power of supramolecular chemistry and bioconjugation to enable direct cytosolic delivery of biomacromolecules. We utilize programmable nanotechnologies, including polymers and gold nanoparticles, to generate highly versatile supramolecular delivery vehicles capable of unique cellular interactions and featuring therapeutically relevant pharmacokinetic properties.

Direct Cytosolic Delivery of Proteins through Co-engineering of Proteins and Polymeric Delivery Vehicles. J. Am. Chem. Soc. 2020, 142, 9, 4349–4355

 

Regulation of Proteins to the Cytosol Using Delivery Systems with Engineered Polymer Architecture. J. Am. Chem. Soc. 2021, 143, 12, 4758–4765

 

Direct Cytosolic Delivery of Proteins through Coengineering of Proteins and Polymeric Delivery Vehicles. J. Am. Chem. Soc. 2020, 142, 9, 4349–4355

 

 

Selected References:

  1. Adv. Funct. Mater.,  2024
  2. Chem. Soc. Rev., 2023
  3. Nanoscale, 2023
  4. ACS Nano, 2023
  5. ACS Nano, 2022
  6. J. Am. Chem. Soc. 2020
  7. J. Am. Chem. Soc. 2021
  8. Advanced Therapeutics.
  9. ACS Nano. 2017
  10. ACS Appl. Mater. Interfaces.